


Inhaled CNS Therapeutics

Drugs, Devices, Diseases, Targets and Therapeutics



Inhaled CNS Therapeutics: Drugs, Devices, Diseases, Targets and Therapeutics

Greystone Associates is pleased to announce the publication of a new market study. **Inhaled CNS Therapeutics: Drugs, Devices, Diseases, Targets and Therapeutics** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector.


The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of inhaled CNS therapies on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

CNS Therapeutics and Inhaled Drug Delivery

Delivering drugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs.

These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicated that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

Report Value Matrix



Executive Summary

Drug Delivery Market Dynamics

The Trend toward Self-Administration
Demographic Shifts
Managed Care Initiatives
Growth in Home Healthcare
Technology Market Drivers

CNS Therapeutic Sector Assessment

Alzheimer's
ADHD
Autism
Dementia
Depression
Epilepsy
Migraine
Multiple Sclerosis
Nausea
Pain Management
Parkinson's
Schizophrenia
Sleeping disorders
Stroke

Inhaled Drug Development Factors

Absorption
Bioavailability
Device Design Parameters
Nasal Delivery Pharmacokinetics
Nasal Device Characteristics
Pulmonary Delivery Pharmacokinetics
Pulmonary Device Characteristics

Market Factors

FDA Regulations
Clinical Trials
Impact of Generics

FDA-Approved Inhaled CNS Drug Products

Butorphanol
Imitrex
Migranal
Zomig

Development-Stage Inhaled CNS Drug Products

Apomorphine
Carbetocin
Dronabinol
Dihydroergotomine
Emitasol
Fentanyl
Ketamine
Loxapine
Morphine
Prochlorperazine
Rylomine
Triazolam

Segment Data, Analysis, and Forecasts

Sector Participant Company Profiles

Feature Summary

- Analyzes and evaluates systemic inhaled drug therapeutics for CNS disorders and diseases and assesses the market potential for existing and probable future products
- Evaluates drug technologies and market development issues
- Provides detailed assessments of CNS therapeutic market segments, market demographics, and business strategies
- Charts product sales data, market share, and forecasts to 2012
- Profiles sector companies, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on future CNS therapeutic products
- Evaluates the impact of economic, technology, and regulatory factors on Inhaled CNS Therapeutics

Report Format and Availability

This report is available electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations. Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Inhaled CNS Therapeutics: Drugs, Devices, Diseases, Targets, and Therapeutics

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$2,850.00	
<input type="checkbox"/>	Site License	\$4,500.00	
<input type="checkbox"/>	Enterprise License	\$6,500.00	
Total Payment (U.S. funds)			



Method of Payment: ___ Company Check ___  ___  ___  ___ Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ CVV _____ Signature _____

Billing Information	Shipping Information
Name:	Name: <input type="checkbox"/> Click here if same as Billing Information
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: